RAPT Therapeutics, Inc.

12 articles about RAPT Therapeutics, Inc.

• RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - June 16, 2021

  6/16/2021

  RAPT Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share.

• RAPT Therapeutics Announces Proposed Public Offering of Common Stock - June 14, 2021

  6/14/2021

  RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that it has commenced an underwritten public offering of $125 million of its common stock.

• RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

  6/13/2021

  RAPT Therapeutics, Inc. announced that the Company plans to report top line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis in a premarket press release and webcast on Monday, June 14, 2021.

• RAPT Therapeutics Reports First Quarter 2021 Financial Results

  5/11/2021

  RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, reported financial results for the first quarter ended March 31, 2021.

• RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR

  3/10/2021

  Tumor model data shows potential of CCR4 antagonist to alter immunosuppressive tumor microenvironment to improve CAR T-cell therapy in solid tumors

• RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

  11/15/2020

  RAPT Therapeutics, Inc. announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.

• Peter Svennilson Elected to RAPT Therapeutics Board of Directors

  6/18/2020

  RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced the election of Peter Svennilson, Managing Partner of The Column Group, to its Board of Directors.

• RAPT Therapeutics to Present at the Jefferies 2020 Virtual Global Healthcare Conference

  5/26/2020

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the Jefferies 2020 Healthcare Conference on Tuesday, June 2nd at 9:30 a.m. Eastern Time.

• RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference

  5/12/2020

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the UBS Virtual Global Healthcare Conference on Tuesday, May 19th at 10:00 a.m. Eastern Time.

• RAPT Therapeutics Announces Proposed Offering of Common Stock - Feb. 04, 2020

  2/4/2020

  RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock.

• RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

  12/10/2019

  RAPT Therapeutics, Inc. announced that Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, LLC, has joined its Board of Directors.

• RAPT Therapeutics Announces Pricing of Initial Public Offering

  10/31/2019

  RAPT Therapeutics, Inc. announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share.